Ratios in Focus: Analyzing Takeda Pharmaceutical Co ADR (TAK)’s Price-to-Cash and Price-to-Free Cash Flow

In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $14.22 down -2.20% from its previous closing price of $14.54. In other words, the price has decreased by -$2.20 from its previous closing price. On the day, 2.7 million shares were traded. TAK stock price reached its highest trading level at $14.421 during the session, while it also had its lowest trading level at $14.175.

Ratios:

For a deeper understanding of Takeda Pharmaceutical Co ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.28. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.65.

On July 19, 2022, Cowen Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $21 to $24.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 23 ’24 when Giles Richard Platford bought 19,073 shares for $14.94 per share.

TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of TAK for $29,999,994 on Jan 24 ’24. The 10% Owner now owns 3,755,583 shares after completing the transaction at $8.10 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 45075410944 and an Enterprise Value of 5316228415488. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 46.59, and their Forward P/E ratio for the next fiscal year is 30.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2329.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.52 while its Price-to-Book (P/B) ratio in mrq is 0.92. Its current Enterprise Value per Revenue stands at 1.205 whereas that against EBITDA is 4.527.

Stock Price History:

Over the past 52 weeks, TAK has reached a high of $15.63, while it has fallen to a 52-week low of $12.57. The 50-Day Moving Average of the stock is -1.37%, while the 200-Day Moving Average is calculated to be 1.70%.

Shares Statistics:

For the past three months, TAK has traded an average of 2.17M shares per day and 2109600 over the past ten days. A total of 3.16B shares are outstanding, with a floating share count of 3.15B. Insiders hold about 0.02% of the company’s shares, while institutions hold 5.06% stake in the company. Shares short for TAK as of 1726185600 were 8388293 with a Short Ratio of 3.86, compared to 1723680000 on 6427049. Therefore, it implies a Short% of Shares Outstanding of 8388293 and a Short% of Float of 0.26.

Dividends & Splits

According to the company, the forward annual dividend rate for TAK is 0.29, from 188.0 in the trailing year. Against a Trailing Annual Dividend Yield of 12.929849The stock’s 5-year Average Dividend Yield is 4.71.

Most Popular